Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 7Sarcoma 3Thyroid Neoplasms 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Extensive Stage 1Proteinuria 1Platinum-resistant Ovarian Cancer (PROC) 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Melanoma 1Limited Stage Small Cell Lung Cancer 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

sparsentan 1anlotinib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Proteinuria × anlotinib × Clear all
NCT07358520 2026-01-22

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

Fudan University

Phase 4 Not yet recruiting
40 enrolled

Proteinuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡